KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $37.00

KalVista Pharmaceuticals (NASDAQ:KALV) had its price objective raised by HC Wainwright from $27.00 to $37.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ FY2030 earnings at $5.90 EPS.

A number of other equities research analysts have also issued reports on the stock. Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Needham & Company LLC increased their price target on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. JMP Securities lifted their price target on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a research report on Friday, September 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV opened at $16.80 on Friday. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $19.00. The stock has a market cap of $849.17 million, a PE ratio of -4.25 and a beta of -0.14. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The stock has a 50 day moving average price of $14.57 and a 200 day moving average price of $13.61.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million for the quarter, compared to analyst estimates of $6.03 million. Equities research analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insider Activity at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 5,296 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $71,231.20. Following the completion of the transaction, the insider directly owned 131,831 shares in the company, valued at $1,773,126.95. This trade represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 7,294 shares of KalVista Pharmaceuticals stock in a transaction on Monday, December 8th. The shares were sold at an average price of $16.51, for a total value of $120,423.94. Following the completion of the sale, the chief executive officer directly owned 424,520 shares of the company’s stock, valued at $7,008,825.20. The trade was a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 31,329 shares of company stock worth $437,371. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its holdings in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $55,000. Wolverine Asset Management LLC acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $57,000. KLP Kapitalforvaltning AS purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $63,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of KalVista Pharmaceuticals during the second quarter worth about $81,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.